

Nicola j Goodson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7522722/publications.pdf>

Version: 2024-02-01

69
papers

2,376
citations

304602

22
h-index

206029

48
g-index

71
all docs

71
docs citations

71
times ranked

2824
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. <i>Arthritis and Rheumatism</i> , 2002, 46, 2010-2019.	6.7	328
2	Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort. <i>Arthritis and Rheumatism</i> , 2005, 52, 2293-2299.	6.7	256
3	British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). <i>Rheumatology</i> , 2009, 48, 436-439.	0.9	170
4	Association of the HLA*DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 359-369.	6.7	161
5	Coronary artery disease and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2002, 14, 115-120.	2.0	130
6	The contribution of musculoskeletal disorders in multimorbidity: Implications for practice and policy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 129-144.	1.4	99
7	The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. <i>Arthritis Research and Therapy</i> , 2018, 20, 140.	1.6	93
8	The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101423.	1.4	82
9	Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 367-372.	0.5	80
10	Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 1620-1628.	0.9	72
11	Cardiovascular risk factors associated with the metabolic syndrome are more prevalent in people reporting chronic pain: Results from a cross-sectional general population study. <i>Pain</i> , 2013, 154, 1595-1602.	2.0	61
12	Cardiovascular co-morbidity in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 71-82.	1.4	60
13	Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2020, 59, iv47-iv57.	0.9	60
14	Ageing, musculoskeletal health and work. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 391-404.	1.4	59
15	Comorbid fibromyalgia complicating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and spondyloarthritis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2018, 57, .	0.9	54
16	Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2018, 57, 1453-1460.	0.9	53
17	Systematic review of mental health comorbidities in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 217-225.	1.0	53
18	Magnetic resonance imaging and musculoskeletal ultrasonography detect and characterize covert inflammatory arthropathy in systemic sclerosis patients with arthralgia. <i>Rheumatology</i> , 2010, 49, 2357-2361.	0.9	44

#	ARTICLE	IF	CITATIONS
19	Comorbidity burden in axial spondyloarthritis: a cluster analysis. <i>Rheumatology</i> , 2019, 58, 1746-1754.	0.9	44
20	Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. <i>Rheumatology</i> , 2014, 53, 1595-1603.	0.9	43
21	Vitamin D assessment in primary care: changing patterns of testing. <i>London Journal of Primary Care</i> , 2015, 7, 15-22.	0.9	35
22	Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. <i>Calcified Tissue International</i> , 2017, 101, 375-383.	1.5	25
23	Incorporating natural language processing to improve classification of axial spondyloarthritis using electronic health records. <i>Rheumatology</i> , 2020, 59, 1059-1065.	0.9	25
24	Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. <i>Rheumatology</i> , 2019, 58, 2025-2030.	0.9	23
25	Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). <i>Rheumatology</i> , 2019, 58, 811-819.	0.9	21
26	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2019, 46, 701-709.	1.0	21
27	Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. <i>Rheumatology International</i> , 2017, 37, 239-244.	1.5	20
28	Rheumatoid Arthritis-associated Corneal Ulceration: Mortality and Graft Survival. <i>Ophthalmology</i> , 2013, 120, 682-686.	2.5	18
29	Smoking in spondyloarthritis: unravelling the complexities. <i>Rheumatology</i> , 2020, 59, 1472-1481.	0.9	18
30	The cardiovascular manifestations of rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2006, 18, 135-140.	2.0	15
31	Vitamin D Deficiency in Axial Spondyloarthritis is Associated With Higher Disease Activity. <i>Archives of Rheumatology</i> , 2017, 32, 209-215.	0.3	14
32	Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies. <i>Arthritis Care and Research</i> , 2020, 72, 591-599.	1.5	14
33	Spondyloarthritis: diagnosis and management: summary of NICE guidance. <i>BMJ</i> , The, 2017, 356, j839.	3.0	13
34	Alcohol and disease activity in axial spondyloarthritis: a cross-sectional study. <i>Rheumatology International</i> , 2018, 38, 375-381.	1.5	13
35	Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. <i>Rheumatology</i> , 2021, 60, 3189-3198.	0.9	12
36	Serum urate and obstructive sleep apnoea in severe obesity. <i>Chronic Respiratory Disease</i> , 2015, 12, 238-246.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Should we be morbid about comorbidities in the rheumatic diseases?. <i>Rheumatology</i> , 2013, 52, 1-2.	0.9	9
38	Diffuse idiopathic skeletal hyperostosis and isotretinoin in cystic acne. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015209775-bcr2015209775.	0.2	9
39	Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. <i>Rheumatology</i> , 2021, 60, 5734-5742.	0.9	9
40	Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. <i>Rheumatology</i> , 2021, 60, 4158-4165.	0.9	8
41	Global public interest in infectious and non-infectious arthritis: an evaluation using Google Trends. <i>Rheumatology</i> , 2020, 59, 245-246.	0.9	7
42	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 177.	1.6	5
43	Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1287-1288.	0.5	5
44	Effects of physical activity on vascular function in autoimmune rheumatic diseases: a systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 3107-3120.	0.9	5
45	Thoracic aortic aneurysms in Behçet's disease. <i>Rheumatology</i> , 2017, 56, kew226.	0.9	3
46	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 281.	1.0	3
47	Comment on: Comorbidity burden in axial spondyloarthritis: a cluster analysis: reply. <i>Rheumatology</i> , 2020, 59, 692-693.	0.9	3
48	Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study. <i>Rheumatology International</i> , 2020, 40, 1045-1049.	1.5	3
49	The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2021, , .	0.9	3
50	Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkab089.	0.3	2
51	Cardiac Involvement in Rheumatoid Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, , 121-143.	0.1	1
52	Safe and well tolerated. <i>Rheumatology</i> , 2011, 50, 1942-1943.	0.9	1
53	Smoking and comorbidities in rheumatoid arthritis: what we know and what we can do?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 45-53.	0.3	1
54	Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis. , 2005, , 178-201.		0

#	ARTICLE	IF	CITATIONS
55	38.â€fDoes Treating Early Rheumatoid Arthritis Within the Window of Opportunity Improve Outcomes at 1 Year?. Rheumatology, 2014, 53, i69-i70.	0.9	0
56	200â€fAutoantibodies to Osteoprotegerin and Bone Mineral Density in Axial Spondyloarthritis. Rheumatology, 2016, , .	0.9	0
57	SPONDYLARTHROPATHIES (INCLUDING PSORIATIC ARTHRITIS)099.â€fSMOKING EXPOSURE IS ASSOCIATED WITH INCREASED DISEASE SEVERITY IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR ANKYLOSING SPONDYLITIS. Rheumatology, 2017, 56, .	0.9	0
58	163â€fA multi-centre retrospective study to describe the real world effectiveness of golimumab for treating ankylosing spondylitis (AS) in UK clinical practice. Rheumatology, 2018, 57, .	0.9	0
59	188â€fReal-world data on the use of certolizumab pegol for the treatment of axial spondyloarthritis in clinical practice in Europe: 24-week interim results from a prospective non-interventional cohort study. Rheumatology, 2018, 57, .	0.9	0
60	e50â€fBiologic monotherapy in rheumatoid arthritis: a retrospective observational study of real life practice in the North West. Rheumatology, 2018, 57, .	0.9	0
61	O35â€fMultimorbidity in patients with axial spondyloarthritis: a cluster analysis. Rheumatology, 2019, 58, .	0.9	0
62	THU0377â€f...THE CARDIOVASCULAR ASSOCIATIONS WITH ENTHESITIS AND DACTYLITIS IN PATIENTS WITH SPONDYLOARTHRITIS: RESULTS FROM THE ASAS-COMOSPA STUDY. , 2019, , .		0
63	P62â€fAssessing the effect of increased body mass on response to DMARD treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2020, 59, .	0.9	0
64	P176â€fSelf-management of depression in axial spondyloarthritis using internet-delivered cognitive behavioural therapy: a feasibility study. Rheumatology, 2021, 60, .	0.9	0
65	P103â€fAssessment and diagnosis of the acute hot joint: a systematic review and meta-analysis. Rheumatology, 2021, 60, .	0.9	0
66	Chapter 8 Comorbidity and complications of RA. , 2010, , .		0
67	Osteoprotegerin autoantibodies are independently associated with low hip bone mineral density and increased fracture risk in patients with ankylosing spondylitis. Bone Abstracts, 0, , .	0.0	0
68	Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Reply. Rheumatology Advances in Practice, 2022, 6, rkac011.	0.3	0
69	P216â€fPromoting physical activity using mobile health technology in people living with rheumatoid arthritis: MOTIVATE RA. Rheumatology, 2022, 61, .	0.9	0